GlassScriptPhysician profile
Jodi Susan Ball
NPI 1578881058
$4,106.53
in general payments reported to CMS, 2019-2025
33 companies · $398 in 2025
The $398 reported for 2025 was more than what 75% of Obstetrics & Gynecology providers received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $408 · 2020: $267 · 2021: $945 · 2022: $696 · 2023: $624 · 2024: $768 · 2025: $398.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,520 · Education: $270.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,520.48 |
| Education | $270.03 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $443.14 | 2021-2025 | Veozah |
| Therapeuticsmd, INC. | $440.57 | 2021-2022 | |
| Exeltis, USA INC. | $337.79 | 2019-2025 | Slynd |
| Novo Nordisk INC | $269.34 | 2019-2025 | Wegovy, Saxenda |
| Avion Pharmaceuticals | $257.12 | 2019-2021 | |
| Amgen INC. | $211.29 | 2019-2025 | Evenity, Prolia, Prolia |
| Mayne Pharma Commercial LLC | $211.17 | 2021-2024 | |
| Shield Therapeutics INC | $206.24 | 2024-2025 | |
| Millicent US INC | $196.30 | 2019-2025 | Femlyv, Intrarosa, Femring |
| Pfizer INC. | $166.64 | 2019-2023 | |
| Coopersurgical, INC. | $135.64 | 2020-2024 | Paragard T 380a, Paragard T 380a |
| Abbvie INC. | $134.73 | 2019-2023 | Lo Loestrin Fe, Orilissa |
| Bayer Healthcare Pharmaceuticals INC. | $121.02 | 2021-2025 | |
| Organon LLC | $112.55 | 2021-2025 | Nexplanon, Nuvaring |
| Scynexis, INC. | $101.27 | 2022 |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Agile Therapeutics, INC. | $100.08 | 2021-2022 | |
| Amag Pharmaceuticals, INC. | $91.26 | 2019-2020 | |
| Daiichi Sankyo INC. | $73.38 | 2022-2024 | Injectafer |
| Merck Sharp & Dohme LLC | $73.19 | 2019-2024 | Gardasil 9, Gardasil |
| Mylan Pharmaceuticals INC. | $65.24 | 2021-2022 | |
| Biogen, INC. | $53.23 | 2024-2025 | Zurzuvae |
| Sumitomo Pharma America, INC. | $46.68 | 2024 | Myfembree |
| Hologic Sales and Service, LLC | $44.87 | 2021-2024 | Aptima |
| Takeda Pharmaceuticals U.S.A., INC. | $31.27 | 2021 | |
| Gilead Sciences, INC. | $27.72 | 2023 | |
| Allergan, INC. | $25.13 | 2019 | |
| Medtronic, INC. | $23.56 | 2024 | Venaseal |
| Evofem Biosciences, INC. | $22.09 | 2021 | |
| Roche Diagnostics Corporation | $20.58 | 2021 | |
| Duchesnay USA Incorporated | $16.53 | 2019 | |
| Smith+Nephew, INC. | $16.33 | 2023 | Pico |
| Mission Pharmacal Company | $15.88 | 2019 | |
| Cosette Pharmaceuticals INC. | $14.70 | 2025 | Vyleesi |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jodi Ball listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.